Business

IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery

IBM (NYSE: IBM) Watson Health and Pfizer Inc. (NYSE: PFE) have announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer.

New European study highlights differing priorities in physician's therapy goals when treating advanced lung cancer patients

Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been published in Clinical Lung Cancer. The research examined the primary therapy goal of physicians and their choice of treatment for patients with advanced adenocarcinoma of the lung, after first-line chemotherapy.

A great place to work, according to Science

Abbott is among the best science-based companies to work for in the world. For the 13th consecutive year, the journal Science recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.

Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp

Novartis today opened the 13th International Biotechnology Leadership Camp (BioCamp). Over the course of three days more than 60 selected students from international universities will discuss and explore with biotechnology and business experts how patients around the world can benefit from innovative technologies.

viomedo Provides Access to Innovative Treatment Methods

Information overload is a common and significant problem with most existing clinical trial search platforms or applications. viomedo makes clinical trial information easily accessible to everybody based on a variety of criteria and by following patient-centric approaches. So far, viomedo online platform aggregates about close to 2.000 clinical trials conducted in Germany. viomedo's founder Alexander Puschilov mentioned: "We are convinced, that everybody has the right to get the best possible therapy! This is why we’ve built viomedo to help patients discover and benefit from innovative treatment methods that were previously accessible only to a few lucky patients."

Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLC

Novartis announced today that the European Commission has approved Zykadia® (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib[1]. The approval of Zykadia in the European Union (EU) provides patients with advanced ALK+ NSCLC previously treated with crizotinib a new treatment option that specifically targets the genetic makeup of their cancer.

Novo Nordisk extends programme for children with diabetes in developing countries

Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training. A child in sub-Saharan Africa diagnosed with type 1 diabetes often has a life expectancy of less than a year . As a response to this situation and as a call to action by the International Diabetes Federation, Novo Nordisk established the Changing Diabetes® in Children programme.

Business

More Pharma News ...